Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Summary not available.
Pfizer (NYSE: PFE) announced on October 31, 2025 that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).
The early termination satisfies the HSR Act regulatory review requirements for the proposed acquisition, which had a waiting-period expiry date of November 7, 2025. The transaction remains pending other closing conditions.
Summary not available.
Pfizer (NYSE: PFE) and Astellas announced final Phase 3 EMBARK results showing that XTANDI plus leuprolide reduced the risk of death by 40.3% (HR 0.597; 95% CI 0.444-0.804; p=0.0006) versus leuprolide alone in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
The 8-year overall survival was 78.9% with XTANDI plus leuprolide vs 69.5% with leuprolide. Median follow-up was ~94 months. XTANDI monotherapy showed a numerical but not statistically significant OS improvement (HR 0.83; p=0.1867). Safety was consistent with prior analyses; common adverse events included hot flashes, fatigue and gynecomastia.
Pfizer (NYSE: PFE) reported updated Phase 2 PHAROS results for BRAFTOVI + MEKTOVI in BRAF V600E-mutant metastatic non-small cell lung cancer. In treatment-naïve patients median overall survival was 47.6 months (95% CI 31.3, NE) after a median follow-up of 52.3 months; previously treated patients had median OS 22.7 months after 48.2 months follow-up. Four-year OS rates were 49% (treatment-naïve) and 31% (previously treated). The ORR was 75% (treatment-naïve) and 46% (previously treated). Safety was consistent with prior data; most common TRAEs ≥30% included nausea, diarrhea, fatigue and vomiting. Data presented at ESMO 2025 and published in Journal of Clinical Oncology.
Pfizer (NYSE: PFE) and Astellas announced positive Phase 3 EV-303 (KEYNOTE-905) results for PADCEV plus KEYTRUDA given before and after surgery in cisplatin-ineligible muscle-invasive bladder cancer.
Key results: EFS HR 0.40 (60% risk reduction; median EFS not reached vs 15.7 months), OS HR 0.50 (50% risk reduction; median OS not reached vs 41.7 months), pCR 57.1% vs 8.6%. Two-year EFS 74.7% vs 39.4%; two-year survival 79.7% vs 63.1%.
Safety consistent with known profile; grade ≥3 AEs higher in combination arm. Regulatory discussions planned.
ViiV Healthcare (PFE shareholder) reported 96-week PASO DOBLE results showing Dovato (dolutegravir/lamivudine) is non-inferior to Biktarvy (bictegravir/emtricitabine/TAF) in maintaining virological suppression in 553 virologically suppressed adults who switched regimens.
Key findings: risk difference for HIV-1 RNA ≥50 copies/mL was –0.7% (95% CI –2.1 to 0.7). Dovato had significantly less weight gain (mean difference 1.52kg, 95% CI 0.74–2.29) and fewer drug-related adverse events (7.6% vs 13.4%, p=0.025) through 96 weeks. No resistance was observed in cases of virological failure.
ViiV Healthcare (PFE) reported initial CLARITY Phase I crossover data showing single-dose cabotegravir (CAB LA) injections were more acceptable and better tolerated than lenacapavir (LEN) injections in 63 HIV‑negative adults (data presented 15 Oct 2025).
Key findings: 69% rated CAB LA “totally or very acceptable” vs 48% for LEN (post hoc p=0.019); 90% of participants and 86% of healthcare providers preferred CAB LA; LEN produced 4.4× more injection‑site reactions (538 vs 123).
Pfizer (NYSE: PFE) reported positive topline Phase 3 results from the HER2CLIMB-05 trial on October 14, 2025: first-line maintenance treatment adding TUKYSA (tucatinib) to trastuzumab plus pertuzumab met the primary endpoint with a statistically significant improvement in progression-free survival (PFS) by investigator assessment.
The company said the combination was tolerable with a safety profile consistent with known profiles of each therapy. Results will be presented at a future medical congress and discussed with regulatory authorities. TUKYSA remains approved in later-line settings but is not currently approved for first-line treatment in the United States.
Pfizer (NYSE: PFE) will present research across its infectious disease portfolio at IDWeek 2025 in Atlanta, October 19–22, 2025. Pfizer will feature data in 46 abstracts, including oral, late-breaking and poster sessions on COVID-19, RSV, pneumococcal disease, Lyme, meningococcal disease and other bacterial and viral infections. Presentations include real-world vaccine effectiveness analyses, clinical subanalyses and epidemiology studies across multiple programs.
The program lists session dates/times and directs readers to full prescribing information for referenced vaccines and therapeutics.